Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Antibiotics Market, by Action Mechanism
1.4.2 Global Antibiotics Market, by Drug Class
1.4.3 Global Antibiotics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals
3.2.4 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct – 2020, Jul) Leading Players
Chapter 4. Global Antibiotics Market by Action Mechanism
4.1 Global Cell Wall Synthesis Inhibitors Market by Region
4.2 Global Protein Synthesis Inhibitors Market by Region
4.3 Global DNA Synthesis Inhibitors Market by Region
4.4 Global RNA Synthesis Inhibitors Market by Region
4.5 Global Mycolic Acid Inhibitors Market by Region
Chapter 5. Global Antibiotics Market by Drug Class
5.1 Global Cephalosporin Market by Region
5.2 Global Penicillin Market by Region
5.3 Global Fluoroquinolone Market by Region
5.4 Global Macrolides Market by Region
5.5 Global Carbapenem Market by Region
5.6 Global Aminoglycosides Market by Region
5.7 Global Sulfonamides Market by Region
5.8 Global Others Market by Region
Chapter 6. Global Antibiotics Market by Region
6.1 North America Antibiotics Market
6.1.1 North America Antibiotics Market by Action Mechanism
6.1.1.1 North America Cell Wall Synthesis Inhibitors Market by Country
6.1.1.2 North America Protein Synthesis Inhibitors Market by Country
6.1.1.3 North America DNA Synthesis Inhibitors Market by Country
6.1.1.4 North America RNA Synthesis Inhibitors Market by Country
6.1.1.5 North America Mycolic Acid Inhibitors Market by Country
6.1.2 North America Antibiotics Market by Drug Class
6.1.2.1 North America Cephalosporin Market by Country
6.1.2.2 North America Penicillin Market by Country
6.1.2.3 North America Fluoroquinolone Market by Country
6.1.2.4 North America Macrolides Market by Country
6.1.2.5 North America Carbapenem Market by Country
6.1.2.6 North America Aminoglycosides Market by Country
6.1.2.7 North America Sulfonamides Market by Country
6.1.2.8 North America Others Market by Country
6.1.3 North America Antibiotics Market by Country
6.1.3.1 US Antibiotics Market
6.1.3.1.1 US Antibiotics Market by Action Mechanism
6.1.3.1.2 US Antibiotics Market by Drug Class
6.1.3.2 Canada Antibiotics Market
6.1.3.2.1 Canada Antibiotics Market by Action Mechanism
6.1.3.2.2 Canada Antibiotics Market by Drug Class
6.1.3.3 Mexico Antibiotics Market
6.1.3.3.1 Mexico Antibiotics Market by Action Mechanism
6.1.3.3.2 Mexico Antibiotics Market by Drug Class
6.1.3.4 Rest of North America Antibiotics Market
6.1.3.4.1 Rest of North America Antibiotics Market by Action Mechanism
6.1.3.4.2 Rest of North America Antibiotics Market by Drug Class
6.2 Europe Antibiotics Market
6.2.1 Europe Antibiotics Market by Action Mechanism
6.2.1.1 Europe Cell Wall Synthesis Inhibitors Market by Country
6.2.1.2 Europe Protein Synthesis Inhibitors Market by Country
6.2.1.3 Europe DNA Synthesis Inhibitors Market by Country
6.2.1.4 Europe RNA Synthesis Inhibitors Market by Country
6.2.1.5 Europe Others Market by Country
6.2.2 Europe Antibiotics Market by Drug Class
6.2.2.1 Europe Cephalosporin Market by Country
6.2.2.2 Europe Penicillin Market by Country
6.2.2.3 Europe Fluoroquinolone Market by Country
6.2.2.4 Europe Macrolides Market by Country
6.2.2.5 Europe Carbapenem Market by Country
6.2.2.6 Europe Aminoglycosides Market by Country
6.2.2.7 Europe Sulfonamides Market by Country
6.2.2.8 Europe Others Market by Country
6.2.3 Europe Antibiotics Market by Country
6.2.3.1 Germany Antibiotics Market
6.2.3.1.1 Germany Antibiotics Market by Action Mechanism
6.2.3.1.2 Germany Antibiotics Market by Drug Class
6.2.3.2 UK Antibiotics Market
6.2.3.2.1 UK Antibiotics Market by Action Mechanism
6.2.3.2.2 UK Antibiotics Market by Drug Class
6.2.3.3 France Antibiotics Market
6.2.3.3.1 France Antibiotics Market by Action Mechanism
6.2.3.3.2 France Antibiotics Market by Drug Class
6.2.3.4 Russia Antibiotics Market
6.2.3.4.1 Russia Antibiotics Market by Action Mechanism
6.2.3.4.2 Russia Antibiotics Market by Drug Class
6.2.3.5 Spain Antibiotics Market
6.2.3.5.1 Spain Antibiotics Market by Action Mechanism
6.2.3.5.2 Spain Antibiotics Market by Drug Class
6.2.3.6 Italy Antibiotics Market
6.2.3.6.1 Italy Antibiotics Market by Action Mechanism
6.2.3.6.2 Italy Antibiotics Market by Drug Class
6.2.3.7 Rest of Europe Antibiotics Market
6.2.3.7.1 Rest of Europe Antibiotics Market by Action Mechanism
6.2.3.7.2 Rest of Europe Antibiotics Market by Drug Class
6.3 Asia Pacific Antibiotics Market
6.3.1 Asia Pacific Antibiotics Market by Action Mechanism
6.3.1.1 Asia Pacific Cell Wall Synthesis Inhibitors Market by Country
6.3.1.2 Asia Pacific Protein Synthesis Inhibitors Market by Country
6.3.1.3 Asia Pacific DNA Synthesis Inhibitors Market by Country
6.3.1.4 Asia Pacific RNA Synthesis Inhibitors Market by Country
6.3.1.5 Asia Pacific Mycolic Acid Inhibitors Market by Country
6.3.2 Asia Pacific Antibiotics Market by Drug Class
6.3.2.1 Asia Pacific Cephalosporin Market by Country
6.3.2.2 Asia Pacific Penicillin Market by Country
6.3.2.3 Asia Pacific Fluoroquinolone Market by Country
6.3.2.4 Asia Pacific Macrolides Market by Country
6.3.2.5 Asia Pacific Carbapenem Market by Country
6.3.2.6 Asia Pacific Aminoglycosides Market by Country
6.3.2.7 Asia Pacific Sulfonamides Market by Country
6.3.2.8 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Antibiotics Market by Country
6.3.3.1 China Antibiotics Market
6.3.3.1.1 China Antibiotics Market by Action Mechanism
6.3.3.1.2 China Antibiotics Market by Drug Class
6.3.3.2 Japan Antibiotics Market
6.3.3.2.1 Japan Antibiotics Market by Action Mechanism
6.3.3.2.2 Japan Antibiotics Market by Drug Class
6.3.3.3 India Antibiotics Market
6.3.3.3.1 India Antibiotics Market by Action Mechanism
6.3.3.3.2 India Antibiotics Market by Drug Class
6.3.3.4 South Korea Antibiotics Market
6.3.3.4.1 South Korea Antibiotics Market by Action Mechanism
6.3.3.4.2 South Korea Antibiotics Market by Drug Class
6.3.3.5 Singapore Antibiotics Market
6.3.3.5.1 Singapore Antibiotics Market by Action Mechanism
6.3.3.5.2 Singapore Antibiotics Market by Drug Class
6.3.3.6 Malaysia Antibiotics Market
6.3.3.6.1 Malaysia Antibiotics Market by Action Mechanism
6.3.3.6.2 Malaysia Antibiotics Market by Drug Class
6.3.3.7 Rest of Asia Pacific Antibiotics Market
6.3.3.7.1 Rest of Asia Pacific Antibiotics Market by Action Mechanism
6.3.3.7.2 Rest of Asia Pacific Antibiotics Market by Drug Class
6.4 LAMEA Antibiotics Market
6.4.1 LAMEA Antibiotics Market by Action Mechanism
6.4.1.1 LAMEA Cell Wall Synthesis Inhibitors Market by Country
6.4.1.2 LAMEA Protein Synthesis Inhibitors Market by Country
6.4.1.3 LAMEA DNA Synthesis Inhibitors Market by Country
6.4.1.4 LAMEA RNA Synthesis Inhibitors Market by Country
6.4.1.5 LAMEA Others Market by Country
6.4.2 LAMEA Antibiotics Market by Drug Class
6.4.2.1 LAMEA Cephalosporin Market by Country
6.4.2.2 LAMEA Penicillin Market by Country
6.4.2.3 LAMEA Fluoroquinolone Market by Country
6.4.2.4 LAMEA Macrolides Market by Country
6.4.2.5 LAMEA Carbapenem Market by Country
6.4.2.6 LAMEA Aminoglycosides Market by Country
6.4.2.7 LAMEA Sulfonamides Market by Country
6.4.2.8 LAMEA Others Market by Country
6.4.3 LAMEA Antibiotics Market by Country
6.4.3.1 Brazil Antibiotics Market
6.4.3.1.1 Brazil Antibiotics Market by Action Mechanism
6.4.3.1.2 Brazil Antibiotics Market by Drug Class
6.4.3.2 Argentina Antibiotics Market
6.4.3.2.1 Argentina Antibiotics Market by Action Mechanism
6.4.3.2.2 Argentina Antibiotics Market by Drug Class
6.4.3.3 UAE Antibiotics Market
6.4.3.3.1 UAE Antibiotics Market by Action Mechanism
6.4.3.3.2 UAE Antibiotics Market by Drug Class
6.4.3.4 Saudi Arabia Antibiotics Market
6.4.3.4.1 Saudi Arabia Antibiotics Market by Action Mechanism
6.4.3.4.2 Saudi Arabia Antibiotics Market by Drug Class
6.4.3.5 South Africa Antibiotics Market
6.4.3.5.1 South Africa Antibiotics Market by Action Mechanism
6.4.3.5.2 South Africa Antibiotics Market by Drug Class
6.4.3.6 Nigeria Antibiotics Market
6.4.3.6.1 Nigeria Antibiotics Market by Action Mechanism
6.4.3.6.2 Nigeria Antibiotics Market by Drug Class
6.4.3.7 Rest of LAMEA Antibiotics Market
6.4.3.7.1 Rest of LAMEA Antibiotics Market by Action Mechanism
6.4.3.7.2 Rest of LAMEA Antibiotics Market by Drug Class
Chapter 7. Company Profiles
7.1 GlaxoSmithKline PLC (GSK)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Johnson and Johnson
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Acquisition and Mergers:
7.3 Merck & Co., Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Product Launches and Product Expansions:
7.3.1.2 Approvals:
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Recent strategies and developments:
7.4.4.1 Acquisition and Mergers:
7.4.4.2 Product Launches and Product Expansions:
7.5 Bayer AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Acquisition and Mergers:
7.7.5.2 Partnerships, Collaborations, and Agreements:
7.8 Abbott Laboratories
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.10. Eli Lilly and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense
Unique Offerings 
